Sommaire
Littérature scientifique sur le sujet « MiR-885-5p »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « MiR-885-5p ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "MiR-885-5p"
1
Zu, Yuanqi, Qianqian Wang et Hong Wang. « Identification of miR-885-5p as a Tumor Biomarker : Regulation of Cellular Function in Cervical Cancer ». Gynecologic and Obstetric Investigation 86, no 6 (2021) : 525–32. http://dx.doi.org/10.1159/000520980.
Texte intégralRésumé :
Objectives: MicroRNAs were revealed as biomarkers for early detection or prognosis predictors of cancer and were involved in the progression of cancer. The present study investigated the expression pattern and potential clinical and functional role of miR-885-5p in cervical cancer. Design: A total of 115 pairs of cervical cancer tissue specimens and adjacent nontumor paracancerous tissue specimens were collected from the cervical cancer patients who underwent surgical resection or biopsy without preoperative systemic therapy at Maternity and Child Health Care of Zaozhuang from 2012 to 2014. Participants/Materials, Setting, Methods: The expression levels of miR-885-5p in cervical cancer were measured using the qRT-PCR assay. A follow-up study was conducted, and the Kaplan-Meier method with log-rank test was used to analyze the potential clinical significance of miR-885-5p in cervical cancer. The functional experiments including CCK-8, Transwell migration, and invasion assays were used to investigate the biological function of miR-885-5p in cervical cancer cells. Results: miR-885-5p expression was decreased in tumor tissues and tumor cell lines compared to normal control. Low expression of miR-885-5p was related to lymph node metastasis, late FIGO stage, and shorter overall survival outcome. Ascending expression of miR-885-5p inhibited the proliferative, migratory, and invasive abilities of cervical cancer cells, while downregulation of miR-885-5p promoted these cellular abilities of cervical cancer cells in vitro. Limitations: The patient population size was limited; thus, the clinical significance of miR-885-5p requires further verification. Second, the precise mechanism of miR-885-5p in cervical cancer is still exclusive. In the future studies, a larger sample size will be required to confirm the prognostic value of miR-885-5p in cervical cancer, and the possible targets, as well as the detailed mechanism of miR-885-5p, will be investigated. Conclusions: miR-885-5p expression was decreased in cervical cancer, and downregulation of miR-885-5p promoted the progression of cervical cancer cells. MiR-885-5p may be an independent prognostic predictor and therapeutic target for treating cervical cancer.
2
Domingo, S., C. Solé-Marcé, T. Moline, B. Ferrer et J. Cortés-Hernández. « POS0135 DOWNREGULATION OF miR-885-5p AS A KEY EFFECTOR IN CUTANEOUS LUPUS ERYTHEMATOSUS PATHOGENESIS ». Annals of the Rheumatic Diseases 81, Suppl 1 (23 mai 2022) : 294.1–295. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4501.
Texte intégralRésumé :
BackgroundSkin involvement is common in systemic lupus erythematosus (SLE), with up to 70% of patients developing skin lesions at some point during the course of their disease. Moreover, cutaneous lesions are the first sign of systemic disease in 20% of SLE patients [1]. Skin requires a regulated and undisrupted miRNA profile for a correct development and function. Studies show that miRNAs play a pathogenic role in autoimmune skin diseases such as Psoriasis [2]. Understanding of the role of deregulated miRNAs in CLE may enhance our knowledge about CLE pathogenesis which is currently not understood.ObjectivesIdentify differentially expressed miRNAs in skin lesions to determine their role in CLE pathogenesis.MethodsPaired skin biopsies from CLE lesional (n=20) and non-lesional skin (n=20) were obtained. MiRNA microarray screening was performed using TaqMan MicroRNA Array. Validation was performed in a new cohort of FFPE skin samples by qRT-PCR (n=20). In situ hybridization was performed to identify the skin cell type involved in selected miRNAs. Next, in vitro experiments using primary skin and immune cells were performed in order to discover their role in CLE pathogenesis. A microarray screening and luciferase assay were performed to find miR-885-5p altered gene expression, molecular pathways and target genes.ResultsMiR-885-5p was found downregulated in CLE lesional skin (-4.45 fold, pvalue<0,01, respectively). Results were confirmed in a validation cohort. In situ hybridization revealed miR-885-5p was located in the epidermal keratinocytes in CLE non-lesional skin. Healthy keratinocytes presented an increased miR-885-5p expression compared with other relevant cell types such as fibroblasts (p<0.001) or PBMCs (p<0.001). Moreover stimulation with IFNα and UVB promoted a marked long-lasting downregulation of miR-885-5p (IFNα, 24h -67 fold (p<0.001); UVB, 24h -70 fold (p<0.001)).Gene microarray of anti-miR-885-5p keratinocytes showed that the unique gene that was upregulated in all anti-miR-885-5p conditions was PSMB5. In vitro experiments demonstrated that PSMB5 is a direct target of miR-885-5p (74% of reduction p<0.001) and it is involved in epidermal inflammation by enhancing NFKB and inflammatory cytokines IL-1β, TNFα and CXCL8. In addition, we observed immune recruitment in UVB stimulated anti-miR885-5p keratinocytes and we found that this immune migration is mediated via miR-885-5p direct binding of TRAF1 and subsequent chemokine CCL5, CCL20, CXCL8 and S100A7 secretion.ConclusionOur findings demonstrate that CLE lesions present a downregulation of miR-885-5p that is strongly implicated in CLE pathogenesis. Moreover, miRNA applicability as therapeutics makes the discovered miRNAs promising candidates for novel therapy in CLE, as there is a need to develop new therapies for refractory cases and to avoid current treatment significant side effects.References[1]Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013; 27(3):391-404.[2]Sonkoly E et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One. 2007. 11;2(7):e610.Disclosure of InterestsNone declared
3
Gui, Junhao, Yaping Tian, Xinyu Wen, Wenhui Zhang, Pengjun Zhang, Jing Gao, Wei Run, Liyuan Tian, Xingwang Jia et Yanhong Gao. « Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies ». Clinical Science 120, no 5 (19 novembre 2010) : 183–93. http://dx.doi.org/10.1042/cs20100297.
Texte intégralRésumé :
Circulating miRNAs (microRNAs) are emerging as promising biomarkers for several pathological conditions, and the aim of this study was to investigate the feasibility of using serum miRNAs as biomarkers for liver pathologies. Real-time qPCR (quantitative PCR)-based TaqMan MicroRNA arrays were first employed to profile miRNAs in serum pools from patients with HCC (hepatocellular carcinoma) or LC (liver cirrhosis) and from healthy controls. Five miRNAs (i.e. miR-885-5p, miR-574-3p, miR-224, miR-215 and miR-146a) that were up-regulated in the HCC and LC serum pools were selected and further quantified using real-time qPCR in patients with HCC, LC, CHB (chronic hepatitis B) or GC (gastric cancer) and in normal controls. The present study revealed that more than 110 miRNA species in the serum samples and wide distribution ranges of serum miRNAs were observed. The levels of miR-885-5p were significantly higher in sera from patients with HCC, LC and CHB than in healthy controls or GC patients. miR-885-5p yielded an AUC [the area under the ROC (receiver operating characteristic) curve] of 0.904 [95% CI (confidence interval), 0.837–0.951, P<0.0001) with 90.53% sensitivity and 79.17% specificity in discriminating liver pathologies from healthy controls, using a cut off value of 1.06 (normalized). No correlations between increased miR-885-5p and liver function parameters [AFP (α-fetoprotein), ALT (alanine aminotransferase), AST (aspartate aminotransferase) and GGT (γ-glutamyl transpeptidase)] were observed in patients with liver pathologies. In summary, miR-885-5p is significantly elevated in the sera of patients with liver pathologies, and our data suggest that serum miRNAs could serve as novel complementary biomarkers for the detection and assessment of liver pathologies.
4
Petric, Rok, Barbara Gazic, Katja Goricar, Vita Dolzan, Radan Dzodic et Nikola Besic. « Expression of miRNA and Occurrence of Distant Metastases in Patients with Hürthle Cell Carcinoma ». International Journal of Endocrinology 2016 (2016) : 1–6. http://dx.doi.org/10.1155/2016/8945247.
Texte intégralRésumé :
Background. Hürthle cell thyroid carcinoma (HCTC) is a rare type of thyroid carcinoma. In the present study, we investigated whether the expression of miRNAs of interest is associated with the occurrence of metastases in patients with HCTC.Materials and Methods. In 39 patients with HCTC (22 with nonmetastatic and 17 with regional or distant metastatic disease), the expression levels of six miRNAs (miR-138, miR-183, miR-221, miR-222, miR-768-3p, and miR-885-5p) and U6 snRNA as endogenous control were determined in FFPE samples of primary tumor and normal thyroid tissue using TaqMan miRNA assays.Results. In patients with HCTC, miR-138 and miR-768-3p were downregulated in tumor samples compared to normal tissue (p=0.013andp=0.010, resp.). These two miRNAs were also significantly downregulated in tumor samples of patients with metastatic disease (p=0.030andp=0.048, resp.) but not in patients with nonmetastatic disease (p=0.249andp=0.101, resp.). In patients with nonmetastatic disease, miR-221 and miR-885-5p were slightly, albeit significantly, upregulated in tumorous compared to normal tissue (p=0.042andp=0.027, resp.).Conclusion. Expression of miRNA (miR-183, miR-221, and miR-885-5p) in tumor tissue is associated with the occurrence of distant metastases in patients with HCTC.
5
Yamano, Tomoki, Shuji Kubo, Emiko Sonoda, Tomoko Kominato, Kei Kimura, Michiko Yasuhara, Kozo Kataoka et al. « Assessment of circulating microRNA specific for patients with familial adenomatous polyposis ». PLOS ONE 16, no 5 (4 mai 2021) : e0250072. http://dx.doi.org/10.1371/journal.pone.0250072.
Texte intégralRésumé :
Circulating microRNAs (miRNAs) are considered promising biomarkers for diagnosis, prognosis, and treatment efficacy of diseases. However, usefulness of circulating miRNAs as biomarkers for hereditary gastrointestinal diseases have not been confirmed yet. We explored circulating miRNAs specific for patients with familial adenomatous polyposis (FAP) as a representative hereditary gastrointestinal disease. Next-generation sequencing (NGS) indicated that plasma miR-143-3p, miR-183-5p, and miR-885-5p were candidate biomarkers for five FAP patients compared to three healthy donors due to moderate copy number and significant difference. MiR-16-5p was considered as an internal control due to minimum difference in expression across FAP patients and healthy donors. Validation studies by real-time PCR showed that mean ratios of maximum expression and minimum expression were 2.2 for miR-143-3p/miR-16-5p, 3.4 for miR-143-3p/miR-103a-3p, 5.1 for miR-183-5p/miR-16-5p, and 4.9 for miR-885-5p/miR-16-5p by using the samples collected at different time points of eight FAP patients. MiR-143-3p/16-5p was further assessed using specimens from 16 FAP patients and 7 healthy donors. MiR-143-3p was upregulated in FAP patients compared to healthy donors (P = 0.04), but not significantly influenced by clinicopathological features. However, miR-143-3p expression in colonic tumors was rare for upregulation, although there was a significant difference by existence of desmoid tumors. MiR-143-3p transfection significantly inhibited colorectal cancer cell proliferation compared to control microRNA transfection. Our data suggested regulation of miR-143-3p expression differed by samples (plasma or colonic tumors) in most FAP patients. Upregulation of plasma miR-143-3p expression may be helpful for diagnosis of FAP, although suppressive effect on tumorigenesis seemed insufficient in FAP patients.
6
Inomistova, M., N. Khranovska, O. Skachkova, G. Klymnyuk et S. Demydov. « Significance of miR-885-5p in neuroblastoma outcome ». Studia Biologica 9, no 3–4 (2015) : 23–30. http://dx.doi.org/10.30970/sbi.0903.450.
Texte intégral
7
Gioffré, Sonia, Mattia Chiesa, Daniela Maria Cardinale, Veronica Ricci, Chiara Vavassori, Carlo Maria Cipolla, Serge Masson et al. « Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients : Diverging Effects of Doxorubicin and Epirubicin ». Journal of Clinical Medicine 9, no 5 (11 mai 2020) : 1418. http://dx.doi.org/10.3390/jcm9051418.
Texte intégralRésumé :
Anthracyclines are anti-neoplastic drugs presenting cardiotoxicity as a side effect. Cardiac troponins (cTn) and echocardiography are currently used to assess cardiac damage and dysfunction, but early biomarkers identifying patients in need of preventive treatments remain a partially met need. Circulating microRNAs (miRNAs) represent good candidates, so we investigated their possible roles as predictors of troponin elevation upon anthracycline treatment. Eighty-eight female breast cancer patients administered with doxorubicin (DOX) or epirubicin (EPI) were divided into four groups basing on drug type and cTn positive (cTn+) or negative (cTn−) levels: DOX cTn−, DOX cTn+, EPI cTn− and EPI cTn+. Blood was collected at baseline, during treatment, and at follow-up. We identified plasma miRNAs of interest by OpenArray screening and single assay validation. Our results showed miR-122-5p, miR-499a-5p and miR-885-5p dysregulation in DOX patients at T0, identifying a signature separating, with good accuracy, DOX cTn− from DOX cTn+. No miRNAs showed differential expression in EPI subjects. Conversely, an anthracycline-mediated modulation (regardless of cTn) was observed for miR-34a-5p, -122-5p and -885-5p. Our study indicates specific circulating miRNAs as possible prediction markers for cardiac troponin perturbation upon anthracycline treatment. Indeed, our findings hint at the possible future use of plasma miRNAs to predict the cardiac responsiveness of patients to different anticancer agents.
8
Pirola, Carlos J., et Silvia Sookoian. « MicroRNAs as messengers of liver diseases : has the message finally been decrypted ? » Clinical Science 136, no 5 (mars 2022) : 323–28. http://dx.doi.org/10.1042/cs20211177.
Texte intégralRésumé :
Abstract MicroRNAs (miRNAs), which are regarded as crucial regulators of gene expression and diverse aspects of cell biology, can be present in various body fluids as highly stable molecules. It is also known that miRNAs exert tissue-specific regulation of gene transcription. Large amount of clinical and experimental evidence provided the rationale for raising the intriguing question of whether miRNAs can mediate cell–cell communication. For those reasons, miRNAs have been considered as the ‘Holy Grail’ of biomarkers allowing non-invasive diagnostic screening and early detection of a variety of diseases, including solid and non-solid cancers. In a study published in Clin. Sci. (Lond.) (2011) 120(5):183–193 (https://doi.org/10.1042/CS20100297), Gui et al. investigated the hypothesis that circulating miRNAs could be used to identify patients with liver pathologies. Specifically, the authors profiled circulating miRNAs in patients with hepatocellular carcinoma (HCC), liver cirrhosis (LC), and healthy controls and found that serum miR-885-5p levels were significantly higher in samples of patients with HCC (6.5-fold increase) and LC (8.8-fold increase). In this commentary, we highlight biological aspects associated with mir-122-the ‘liver-specific’ miRNA, which has been associated with a diverse range of liver pathologies. In addition, we discuss the relevance of mir-885-5p as potential biomarker for detecting human cancers. Finally, we provide some clues about how presumably unrelated miRNAs such as miR-122 and miR-885-5p may act in similar biological processes (BPs), making the miRNA regulatory networks more complex than anticipated.
9
Fayyad-Kazan, Mohammad, Rim ElDirani, Eva Hamade, Rania El Majzoub, Haidar Akl, Nizar Bitar, Hussein Fayyad-Kazan et Bassam Badran. « Circulating miR-29c, miR-30c, miR-193a-5p and miR-885-5p : Novel potential biomarkers for HTLV-1 infection diagnosis ». Infection, Genetics and Evolution 74 (octobre 2019) : 103938. http://dx.doi.org/10.1016/j.meegid.2019.103938.
Texte intégral
10
Hosen, Mohammed Rabiul, Philip Roger Goody, Andreas Zietzer, Xu Xiang, Sven Thomas Niepmann, Alexander Sedaghat, Vedat Tiyerili et al. « Circulating MicroRNA-122-5p Is Associated With a Lack of Improvement in Left Ventricular Function After Transcatheter Aortic Valve Replacement and Regulates Viability of Cardiomyocytes Through Extracellular Vesicles ». Circulation 146, no 24 (13 décembre 2022) : 1836–54. http://dx.doi.org/10.1161/circulationaha.122.060258.
Texte intégralRésumé :
Background: Transcatheter aortic valve replacement (TAVR) is a well-established treatment option for high- and intermediate-risk patients with severe symptomatic aortic valve stenosis. A majority of patients exhibit improvements in left ventricular ejection fraction (LVEF) after TAVR in response to TAVR-associated afterload reduction. However, a specific role for circulating microRNAs (miRNAs) in the improvement of cardiac function for patients after TAVR has not yet been investigated. Here, we profiled the differential expression of miRNAs in circulating extracellular vesicles (EVs) in patients after TAVR and, in particular, the novel role of circulating miR-122-5p in cardiomyocytes. Methods: Circulating EV-associated miRNAs were investigated by use of an unbiased Taqman-based human miRNA array. Several EV miRNAs (miR-122-5p, miR-26a, miR-192, miR-483-5p, miR-720, miR-885-5p, and miR-1274) were significantly deregulated in patients with aortic valve stenosis at day 7 after TAVR compared with the preprocedural levels in patients without LVEF improvement. The higher levels of miR-122-5p were negatively correlated with LVEF improvement at both day 7 ( r =−0.264 and P =0.015) and 6 months ( r =−0.328 and P =0.0018) after TAVR. Results: Using of patient-derived samples and a murine aortic valve stenosis model, we observed that the expression of miR-122-5p correlates negatively with cardiac function, which is associated with LVEF. Mice with graded wire injury–induced aortic valve stenosis demonstrated a higher level of miR-122-5p, which was related to cardiomyocyte dysfunction. Murine ex vivo experiments revealed that miR-122-5p is highly enriched in endothelial cells compared with cardiomyocytes. Coculture experiments, copy-number analysis, and fluorescence microscopy with Cy3-labeled miR-122-5p demonstrated that miR-122-5p can be shuttled through large EVs from endothelial cells into cardiomyocytes. Gain- and loss-of-function experiments suggested that EV-mediated shuttling of miR-122-5p increases the level of miR-122-5p in recipient cardiomyocytes. Mechanistically, mass spectrometry, miRNA pulldown, electrophoretic mobility shift assay, and RNA immunoprecipitation experiments confirmed that miR-122-5p interacts with the RNA-binding protein hnRNPU (heterogeneous nuclear ribonucleoprotein U) in a sequence-specific manner to encapsulate miR-122-5p into large EVs. On shuttling, miR-122-5p reduces the expression of the antiapoptotic gene BCL2 by binding to its 3′ untranslated region to inhibit its translation, thereby decreasing the viability of target cardiomyocytes. Conclusions: Increased levels of circulating proapoptotic EV-incorporated miR-122-5p are associated with reduced LVEF after TAVR. EV shuttling of miR-122-5p regulates the viability and apoptosis of cardiomyocytes in a BCL2-dependent manner.
Thèses sur le sujet "MiR-885-5p"
1
MARABITA, FRANCESCO. « Single Nucleotide Polymorphisms and circulating microRNAs for monitoring HCV disease progression : an integrated approach ». Doctoral thesis, Università degli Studi di Milano-Bicocca, 2011. http://hdl.handle.net/10281/29993.
Texte intégralRésumé :
Chronic Hepatitis C Virus (HCV) infection is associated with severe complications such as liver cirrhosis and hepatocellular carcinoma (HCC). For HCV infection, there is a crucial need for novel, preferably non‐invasive tests that could be used to improve the diagnosis and the management programs for patients at high risk of developing severe liver complications, such as cirrhosis and HCC. Classical biochemical markers to follow disease progression show limited potential mainly for invasiveness or little specificity and sensitivity, especially for HCC.
The goal of this work was to discover useful biomarkers of disease progression in the setting of chronic HCV infection. In the first part, a Genome Wide Association Study was carried out to study the genetic variability influencing the natural history of HCV infection. A cohort of patients was genotyped and disease stage was evaluated through a liver biopsy before any antiviral treatment. Although no hits reached a genome-wide significance level, candidate regions showing suggestive association were identified. In particular, the gene region containing the GADD45G gene resulted of particular interest, given its role in cell biology. Conversely, the analysis of covariates revealed that they had a profound impact on the progression of the liver disease. Indeed, the age at infection had a marked effect on fibrosis progression (p < 2E‐16), suggesting that this is the major explanatory variable in our cohort. Male gender (p < 0.05) and HCV genotype 3 (p < 0.01) were also associated to faster fibrosis progression.
The second part of this work focused on the use of circulating microRNA as blood-based biomarker of disease status. We investigated whether specific serum miRNA signatures may be detected in the serum of patients with chronic HCV infection at different stages of liver disease. Individual sera from healthy controls, patients with chronic hepatitis, liver cirrhosis or HCC were tested by high‐throughput qPCR to profile the expression of the whole miRNome. A solid normalization strategy was applied to reduce variability, and 22 miRNAs were considered differentially represented among the four classes (p<0.05 after multiple testing correction) The levels of miR‐122 and miR‐885‐5p specifically and consistently increased in patients with HCV infection compared to healthy controls or patients with Cronh’s disease (p<0.001). miR‐122 concentration changed significantly among groups with different alanine aminotransferase (ALT) activity (p<0.001), showing a positive trend. In summary, serum levels of miR‐122 and miR‐885‐5p were significantly elevated in patients with HCV‐associated liver pathologies. Our data show the potential use of serum miRNA as novel biomarker in the setting of chronic HCV infection.
Actes de conférences sur le sujet "MiR-885-5p"
1
Zhang, Zhuhong, Jing Yin, Dan Lv, Chenghu Liu, Jian Yang, Antao Chang, Peiqing Sun et al. « Abstract 3081 : miR-885-5p, a p53-activated microRNA, inhibits the Wnt/β-catenin signaling pathway and hepatocellular carcinoma metastasis. » Dans Proceedings : AACR 104th Annual Meeting 2013 ; Apr 6-10, 2013 ; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3081.
Texte intégral